Aidoc Expands AI Service to X-ray, Receiving FDA 510(k) Clearance for Pneumothorax

What To Know

  • “This FDA clearance further validates the breadth of our AI platform, going beyond specific AI algorithms to act as a healthcare AI hub for the enterprise's cross-specialty needs.
  • By bringing radiologists and proceduralists to the same AI platform, we enable enhanced collaboration across departments and systems to deliver patients with the right treatment at the right time.

Aidoc, the leading provider of healthcare AI solutions, today announced that it received FDA 510(k) clearance for its triage and notification of pneumothorax on X-ray exams.

Aiodic notes, a one-stop partner for the enterprise’s clinical AI needs, Aidoc’s other seven FDA-cleared solutions are already implemented across U.S. health systems, flagging and communicating suspected pathologies in CT exams – and now have expanded to the high volume X-ray modality.

Aidoc’s newly FDA-cleared solution runs on all X-ray machines including portable ones, and is designed to analyze X-ray images. It automatically flags positive cases of pneumothorax, facilitating physicians to read X-rays in a timely manner.

The ability to quickly identify pneumothorax is imperative as it can worsen rapidly and result in respiratory or cardiac failure. This however is easier said than done, due to the extensive imaging volumes radiologists have to continuously examine. Aidoc’s highly accurate AI pneumothorax algorithm addresses this challenge by analyzing X-rays, flagging, and notifying physicians of the suspected findings.

“We’re very excited about this important milestone,” said Elad Walach, CEO of Aidoc. “This FDA clearance further validates the breadth of our AI platform, going beyond specific AI algorithms to act as a healthcare AI hub for the enterprise’s cross-specialty needs. This includes ER, ICU, outpatient centers, inpatient admissions, and the coordination of care and communication among providers. By bringing radiologists and proceduralists to the same AI platform, we enable enhanced collaboration across departments and systems to deliver patients with the right treatment at the right time.”

Aidoc’s AI platform processes high volumes of scans and images without disrupting the physician’s workflow. Existing partners of Aidoc, who add the pneumothorax solution to their portfolio, will not require any additional integration, infrastructure, or maintenance efforts.

 

SourceAidoc,
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

XT-Thrive® Drug Master File (DMF) Accepted by the FDA | Reports X-Therma

X-Therma notes this DMF covers the Chemistry, Manufacturing and Controls (CMC) for this key chemistry innovation, which enables non-toxic cryopreservation for life-saving regenerative medicines.

Simpson Interventions Receives FDA Breakthrough Device Designation for Acolyte™ Image Guided Crossing and Re-Entry Catheter System

Simpson Interventions is committed to collaborating closely with the FDA and other stakeholders to advance the development and regulatory review of the Acolyte Image Guided Crossing and Re-Entry Catheter System. The company looks forward to bringing this revolutionary technology to clinicians, and patients in need.

Transforming Tricuspid Valve Care: FDA Gives Green Light to Abbott’s TriClip™

"The U.S. approval of TriClip is a significant advancement for people suffering from tricuspid regurgitation, a heart condition that negatively impacts their quality of life and puts them at grave risk of serious health issues," said Paul Sorajja, M.D., the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation and director of the Center for Valve and Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital and co-principal investigator of the TRILUMINATE™ Pivotal trial. "With TriClip, physicians can offer patients a therapy option backed by excellent safety and effectiveness to help restore tricuspid native valve performance without subjecting them to high-risk open-heart surgery that may not be feasible for individuals with TR who are generally older and sicker."

HeadaTerm 2: The Most Affordable FDA Cleared Innovative OTC Anti-Migraine Device

This make it one of the only wearable OTC anti-migraine device that is available without a prescription in the U.S.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version